Vitamin D and lung immune cells in lung fibrosis
Part of Lungs & breathing clinical trials.
This study looks at how vitamin D affects immune cells in the lungs of people with a lung scarring condition called idiopathic pulmonary fibrosis (IPF) or other similar lung diseases. It tests if vitamin D levels are linked to how these cells work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of IPF, another lung scarring disease, or lung cancer.
- You are able to understand and speak Danish.
- You are willing to sign a consent form to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This study is looking at people with Idiopathic Pulmonary Fibrosis (IPF), a type of lung scarring. Researchers will use medical records to see if they can better predict how the disease will progress over time.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.